MAML2 and neoplasm: SIRT1 is a NAD+-dependent Class III histone deacetylase that has been shown to antagonize cellular senescence [35] and is also an established negative regulator of CRTC2, and possibly CRTC1 as well [36], suggesting that this integration event could enhance CRTC1-MAML2 expression in this tumor.